Supriya Lifescience Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fmotskrq8qrrl3agesm1b6rq.pdf

Key Takeaways


Margin Transformation

Saloni Wagh: "on that annualized basis, we are expecting our margin trend to be somewhere between that 32% to 34% moving forward. And year-on-year, definitely you will see that in terms of the actual growth in the EBITDA number and the PAT number that you will be able to see very clearly."

Capacity Expansion & Module E


Export Mix & Regulated Market Shift

Dr. Satish Wagh: "we are confident that we are telling our customers, please don't ask for any reduction in the price. This is our ideology because you should be happy that rather than a non-GMP plant, you are buying the material, even intermediate API from a US FDA plant."

New Products & Pipeline


CMO-CDMO & Ambernath


Competitive Moat & Strategy

Dr. Satish Wagh: "if you say and go to them and put GMP, they will not get GMP for another 10 years. That much we know because we have been going to China for at least not less than 25 years."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth20%+ YoYOngoing annual target
H2 outperformanceH2 revenue slightly higher than H1; absolute EBITDA and PAT highest so far this yearFY25 H2
Annualized EBITDA margin32% to 34%Moving forward, stabilized basis
Module E commercial startCommercial production beginsQ3 FY25
Module E full utilizationMaximum capacity utilization reachedFY27 exit (quarterly basis)
New products launchInitial traction in semi-regulated marketsQ3 FY25
New products contribution~15% of toplineIn about 2 years
DSM food volumesFeed and food volumes beginNext year (FY26)
DSM pharma peak volume₹50–60 crore annual run-rate, potentially higherFY27, peak in 3 years
API advanced intermediate CMO3–4 opportunities start commercial revenueQ4 FY25 or Q1 FY26
Ambernath formulation revenueCommercial revenue beginsQ4 FY25 or Q1 FY26
Cancer detection kit commercializationCommercial revenue beginsIn next 2–3 years
FY27 revenue base case₹1,000 crore (conservative; upsides not yet budgeted)FY27
China NMPA auditScheduledDecember 2024
Whey protein FSSAI licenseExpectedEnd of Q3 FY25

Key Metrics

MetricQ2 FY25
Revenue₹166 cr, +19% YoY from ₹140 cr in Q2 FY24
H1 FY25 revenue₹327 cr, +20% YoY from ₹272 cr in H1 FY24
EBITDA₹64.7 cr, doubled from ₹31.7 cr in Q2 FY24
EBITDA margin39%, up from 23% in Q2 FY24
H1 FY25 EBITDA₹127.3 cr, +68% YoY from ₹76 cr in H1 FY24
PAT₹46 cr, nearly doubled from ₹24 cr in Q2 FY24
PAT margin28%, up from 17% in Q2 FY24
H1 FY25 PAT₹91 cr, +73% YoY from ₹52 cr in H1 FY24
Annualized asset turnover ratio2.2, up from 2.1 in the prior period
Debt-to-equity ratio0.01
Export contribution83% of revenue, up from 81% in Q2 FY24
LATAM share of revenue19%, up from 13% in Q2 FY24
Regulated markets share~52% to 53% of total revenue
Backward integrated products15 products, generating 74% of revenue, up from 69% last quarter
Total production capacity~1,020 KL (540 KL existing + ~400 KL module E + ~70 KL Ambernath)
Capacity utilization (pre-module E)76%+
FY27 revenue guidance₹1,000 cr (base case)
Annualized EBITDA margin guidance32% to 34% moving forward
Revenue growth guidance20%+ year-on-year
New products contribution (2 years out)~15% of topline (per an analyst's math)
DSM project annual revenue potential₹50–₹60 cr starting FY27, with upside potential
CAPEX for module A, B, C repairs~₹100 cr, to be taken over phases